SI
CATX icon

Sofinnova Investments’s Perspective Therapeutics CATX Stock Holding History

Sofinnova Investments’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-120,632
Closed -$1.61M – 65
2024
Q3 		$1.61M Sell
120,632
-11,457
-9% -$152K 0.13% 53
2024
Q2 		$1.32M Buy
132,089
+89,078
+207% +$1.29M 0.07% 67
2024
Q1 		$512K Buy
+43,011
New +$367K 0.03% 66

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sofinnova Investments's CATX Position: Q4 2024 in Review

Sofinnova Investments sold out of Perspective Therapeutics (CATX) in Q4 2024, closing a stake of 120,632 shares — an estimated $1.61M sold.

Sofinnova Investments first reported a position in CATX in Q1 2024 and held it in 3 quarters. The position peaked at $1.61M in Q3 2024. 135 funds tracked by Wall St. Rank hold CATX as of Q4 2024.

  • Sofinnova Investments reported no remaining Perspective Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sofinnova Investments sold 120,632 Perspective Therapeutics shares in Q4 2024, an estimated $1.61M.
  • Sofinnova Investments first reported a position in Perspective Therapeutics in Q1 2024 and held it in 3 quarters.
  • Sofinnova Investments's Perspective Therapeutics position peaked at $1.61M in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2024.

Based on Sofinnova Investments's 13F filing for Q4 2024, filed 14 Feb 2025.